Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 07/27 10:00:00 pm
81.79 USD   +0.91%
07/26 TEXAS INSTRUMEN : Gilead Sciences and McDonald's slip; Texas Instrum..
07/26 MARKETS RIGHT N : US stocks turn lower in midday trade
07/26 S&P 500 MOVERS : Cnc, txn
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Texas Instruments : Gilead Sciences and McDonald's slip; Texas Instruments rises

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/26/2016 | 10:35pm CEST

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:

Gilead Sciences Inc., down $7.50 to $81.05

The hepatitis C drug maker reported weak sales and cut its revenue estimates for the year.

McDonald's Corp., down $5.69 to $121.71

The world's largest burger chain posted disappointing U.S. sales growth in the second quarter.

Texas Instruments Inc., up $5.20 to $71.42

The chipmaker's results were better than expected and it gave a strong outlook for the third quarter.

Las Vegas Sands Corp., up $2.82 to $50.62

The casino operator reported weak results but said there are signs its business is getting more stable in Macau.

United Technologies Corp., up $3.24 to $107.89

The profit and sales at the maker of elevators, jet engines and other machinery were better than expected and it raised the low end of its annual projections.

Celanese Corp., down $4.28 to $65.73

The chemical company's sales fell short of estimates.

Centene Corp., down $6.39 to $68.87

Investors were disappointed that the health insurer suggested it's not interested in making an acquisition.

Sirius XM Holdings Inc., up 20 cents to $4.35

The satellite radio company raised its guidance after reporting strong revenue and subscriber growth.

Copyright 2016 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed., source Associated Press News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES, INC.
07/26 TEXAS INSTRUMENTS : Gilead Sciences and McDonald's slip; Texas Instruments rises
07/26 MARKETS RIGHT NOW : US stocks turn lower in midday trade
07/26 S&P 500 MOVERS : Cnc, txn
07/26 NASDAQ 100 MOVERS : Gild, txn
07/26 GILEAD SCIENCES : cuts 2016 sales forecast, cites hepatitis C drugs
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 2nd Update
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 3rd Update
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- Update
07/25 GILEAD SCIENCES : Results of Operations and Financial Condition, Financial State..
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19%
More news
Sector news : Bio Therapeutic Drugs
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised -- Update
07/27DJAmgen Profit Rises 13%, 2016 Outlook Raised
07/27 GSK chases next biotech asthma drug with 175 million pounds J&J deal
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07/27 Investing In Biotech And The Internet Of Things (Podcast With Dana Blankenhor..
07/27 BIOTECH DAILY DIGEST : Gilead's Thud, Tobira Gets A Shout-Out, Spotlight On Adva..
07/27 GILEAD : Too Cheap To Ignore
07/27 Big Spike In Dark Pool Bets Against Gilead
07/27 Finding Some Of The Best-Quality Dividend Growth Stocks Using The Piotroski F..
Advertisement
Financials ($)
Sales 2016 30 548 M
EBIT 2016 20 390 M
Net income 2016 14 675 M
Debt 2016 5 660 M
Yield 2016 2,29%
P/E ratio 2016 7,57
P/E ratio 2017 7,19
EV / Sales 2016 3,72x
EV / Sales 2017 3,59x
Capitalization 107 944 M
More Financials
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 108 $
Spread / Average Target 33%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-19.90%107 944
AMGEN, INC.3.29%125 957
CELGENE CORPORATION-11.34%82 247
REGENERON PHARMACEUTIC..-27.26%41 850
VERTEX PHARMACEUTICALS..-24.52%23 493
ACTELION LTD23.35%19 965
More Results